Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characterization of the Pharmacokinetic and Pharmacodynamic Profile of Apraglutide, a Glucagon-Like Peptide-2 Analog, in Healthy Volunteers.
Bolognani F, Kruithof AC, Schulthess P, Machacek M, de Kam ML, Bergmann KR, van Gent M, Moerland M, Crenn P, Greig G, Gal P. Bolognani F, et al. Among authors: kruithof ac. J Pharmacol Exp Ther. 2023 Aug;386(2):129-137. doi: 10.1124/jpet.123.001582. Epub 2023 Jun 14. J Pharmacol Exp Ther. 2023. PMID: 37316329 Clinical Trial.
A randomized single and multiple ascending dose study in healthy volunteers of LTI-291, a centrally penetrant glucocerebrosidase activator.
den Heijer JM, Kruithof AC, van Amerongen G, de Kam ML, Thijssen E, Grievink HW, Moerland M, Walker M, Been K, Skerlj R, Justman C, Dudgeon L, Lansbury P, Cullen VC, Hilt DC, Groeneveld GJ. den Heijer JM, et al. Among authors: kruithof ac. Br J Clin Pharmacol. 2021 Sep;87(9):3561-3573. doi: 10.1111/bcp.14772. Epub 2021 Mar 2. Br J Clin Pharmacol. 2021. PMID: 33576113 Free PMC article.
Effect of Food on the Pharmacokinetics of 2 Formulations of DRL-17822, a Novel Selective Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Males.
Kruithof AC, Kumar R, Stevens J, de Kam ML, Gautam A, Alikunju S, Padhi BK, Kulkarni S, Raghuvanshi RS, Gandhi R, Burggraaf J, Kamerling IMC. Kruithof AC, et al. Clin Pharmacol Drug Dev. 2019 Nov;8(8):1042-1052. doi: 10.1002/cpdd.707. Epub 2019 Jun 10. Clin Pharmacol Drug Dev. 2019. PMID: 31183985 Clinical Trial.
Interactions of sugammadex with various anticoagulants
.
Kruithof AC, Kluft C, de Kam PJ, Laterveer GH, Moerland M, Burggraaf J. Kruithof AC, et al. Int J Clin Pharmacol Ther. 2020 Jul;58(7):395-403. doi: 10.5414/CP203733. Int J Clin Pharmacol Ther. 2020. PMID: 32383642
Lack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low-molecular-weight heparin in healthy subjects.
De Kam PJ, Kruithof AC, van Lierop MJ, Moerland M, Dennie J, Troyer MD, Langdon RB, Gutstein DE, Burggraaf J, El Galta R. De Kam PJ, et al. Among authors: kruithof ac. Int J Clin Pharmacol Ther. 2014 Aug;52(8):631-41. doi: 10.5414/CP202091. Int J Clin Pharmacol Ther. 2014. PMID: 24800921 Clinical Trial.
The mode of action of sugammadex on coagulation.
Kruithof AC, Kluft C, de Kam PJ, Laterveer RH, Moerland M, Burggraaf J. Kruithof AC, et al. Int J Clin Pharmacol Ther. 2021 Feb;59(2):89-98. doi: 10.5414/CP203858. Int J Clin Pharmacol Ther. 2021. PMID: 33155541
16 results